Health Canada has given the green light to a new GLP-1 weight-loss medication taken as a daily pill instead of a weekly injection. Foundayo, manufactured by U.S. multinational pharmaceutical company Eli Lilly, was approved on Nov. 13 in Canada for adults with obesity. It has also been authorized for adults who are overweight and have at least one weight-related health condition, such as high blood pressure or sleep apnea, and it’s approved to help manage Type 2 diabetes.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with A.C.
Contact A.C., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack